Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 30 for “"FOLFOX"”.
-
Mathematical Models of the Role of the Immune System in FOLFOX Therapy for Colorectal Adenocarcinoma
… The current standard-of-care for this cancer is FOLFOX, a chemotherapeutic combination of three drugs, 5-fluoruracil (5-FU), oxaliplatin and folinic acid. Although originally developed as a standard chemotherapy, this combination was found to have significant immune effects, and understanding the …
-
Cognitive and physical function in individuals treated with adjuvant FOLFOX chemotherapy for colon cancer : pilot study
Background: Following chemotherapy, it is estimated that up to 95% of all cancer patients report cognitive changes such as complaints with memory and difficulty concentrating. This condition is referred to as chemotherapy-associated cognitive dysfunction or “chemo brain”. In addition, deficits in …
-
Phenotypic Profiling of Colon Tumor Organoid Monolayers Characterizes a FOLFOX-Induced, AKT-Driven Subpopulation of Chemoresistant Cells
… chemotherapy with multidrug regimens such as FOLFOX (Folinic Acid, 5-Fluorouracil, Oxaliplatin). However, due to high heterogeneity in colon tumors, patient response is variable and tools to predict drug response are few. Additionally, resistance, which can lead to recurrence and metastasis, …
-
Multistate outcome weighted learning for optimal individualized treatment recommendations in metastatic colorectal cancer
… PRIME. Η δοκιμή PRIME συνέκρινε τη θεραπεία FOLFOX+Panitumumab έναντι FOLFOX σε 849 ασθενείς (τελικό αναλυτικό δείγμα από σύνολο 1.183) σε 133 ιατρικά κέντρα 19 χωρών. Η μέθοδος msOWL επεκτείνει το πλαίσιο Outcome Weighted Learning σε δεδομένα διαδικασιών πολλαπλών καταστάσεων. Η νόσος …
-
Which Gene is a Dominant Predictor of Response during FOLFOX Chemotherapy for the Treatment of Metastatic Colorectal Cancer, MTHFR or XRCC1 Gene?
"국문요약 ------------------------------------------- i 차례 ----------------------------------------------- iv 그림 차례 ------------------------------------------- v 표 차례---------------------------------------------- vi I. 서론 ------------------------------------------ 1 II. 연구대상 및 …
-
Expression of Bax Predicts Outcome in Advanced Gastric Cancer Patients Treated With 5-fluorouracil and Platinum Palliative Chemotherapy
… patients) or 5-FU, leucovorin, and oxaliplatin (FOLFOX) (72 patients). Pretreatment tumor biopsy specimens were analyzed for Bax, ERCC1, and TS expression by immunohistochemistry. Results: High expression of Bax, ERCC1 and TS was observed in 49 (38%), 60 (47%), and 48 (38%) patients, …
-
현미부수체 상태에 따른 결장암의 예후와 보조항암요법과의 상관관계
… 상태에 따른 결장암의 특성을 분석하였으며, 75명의 3기 결장암 환자를 대상으로 FOLFOX 또는 capecitabine을 투여한 결과를 후향적으로 분석하였다. MSI 결장암의 경우 5년 생존율은 비슷하였으나 (92.3% vs 85.5% p=0.608) 원발종양이 근위부에 위치하고 (86.7% vs 42.3% p<0.001) 병리학적으로 점액성암의 빈도가 높고 암세포의 분화도가 좋게 나왔다. (p<0.001) 3기 결장암에서 FOLFOX치료를 받은 환자군은 capecitabine 투여를 받은 환자군보다 유의한 생존율 …
-
The role of SPRTN protease in colorectal cancer chemotherapy
… with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX). Both these regiments present similar level of efficacy, and both irinotecan and oxaliplatin have been reported as drugs with the potential to induce relevant amounts of DNA-protein crosslinks (DPCs), a heterogeneous form of DNA lesion in …
-
Σύγκριση του βαθμού καρδιοτοξικότητας του συνδυασμού καπεσιταμιμπής και οξαλιπλατίνας (xelox) έναντι του συνδυασμού 5-fu/lv με οξαλιπλατίνα (folfox) ως συμπληρωματική θεραπεία σε ασθενείς με χειρουργημένο κολοορθικό καρκίνο σταδίου ΙΙ (υψηλού κινδύνου) και ΙΙΙ
… in the study who were treated either with FOLFOX (n=16) or with XELOX (n=54) adjuvant chemotherapy. All patients were subjected to full cardiovascular evaluation at the begging and the end of chemotherapy. Arterial stiffness was assessed by means of pulse wave velocity (PWV) and …
-
Detection and comparison of Circulating Tumor Cells and circulating free DNA at patients with stage III colorectal cancer receiving three or six months of adjuvant chemotherapy
… improving overall survival. Historically, the FOLFOX regimen, consisting of 5-Fluorouracil, Leucovorin, and Oxaliplatin administered over six months, was considered the gold standard. However, the IDEA trial (2018) introduced a paradigm shift by demonstrating that a three-month adjuvant …
-
5-fluorouracil: mechanisms of action (or resistance) in p53-proficient and -deficient colorectal cancer
… propose the use of 5-FU-based treatments (5-FU, FOLFOX) in combination with anti-PD-L1 treatment. Second, in p53-proficient patients, we propose the combination of 5-FU or FOLFOX with class I Entinostat. Further investigations are necessary to support these proposals, particularly in light of the …
-
Tailored chemotherapy based on genomic polymorphisms for metastatic colorectal cancer treated with 5-fluorouracil plus oxaliplatin or irinotecan in Korean patients
배경: 옥살리플라틴과 이리노테칸은 전이성 대장암 환자에서 5-FU와 함께 투여하여 FOLFOX 또는 FOLFIRI용법으로 일차치료로서 가장 많이 사용되는 항암제이다. 본 연구의 목적은 전이성 대장암 환자에서 전향적 연구로서 항암제와 연관된 유전자 다형성을 분석하고 환자에 맞는 약제를 선택하여 일차치료를 진행하여 이에 대한 반응도를 알아보기로 하였다. 방법: 50명의 전이성 대장암 환자에서 말초혈액을 통해 유전자 다형성을 분석하였다. PCR-based RFLP 방법을 사용하여 TS, MTHFR-977, XPD-751, …
-
Studien- und Versorgungsdaten als Grundlage optimierter Therapien solider Tumore
… mKRK. Nach sechs Zyklen Induktion mit FOLFOX plus Panitumumab erhielten 248 Patienten eine Erhaltungstherapie mit 5-FU/Folinsäure mit oder ohne Panitumumab. Die Hinzunahme von Panitumumab verlängerte das progressionsfreie Überleben (HR 0,73; 95 %-KI 0,56–0,94), nicht aber das …
-
Application of pharmacoepidemiological approaches to generate real-world evidence on the use and impact of metastatic colorectal cancer medicines
… of the patients treated with a doublet of FOLFOX or FOLFIRI, 22.3% (N=49) with 5FU, 19.5% (N=43) with cetuximab+FOLFIRI, and 5% (N=11) of patients treated initially with aflibercept+FOLFIRI. Treatment choices for 1L mCRC were made based on patients’ age and gender, tumour RAS status, and …
-
Identification of novel treatment approaches for poor prognostic <i>BRAF</i>MT colorectal cancer
… typically involves doublet chemotherapy (FOLFOX/XELOX/CAPOX or FOLFIRI/XELIRI). Second/third-line therapy combines EGFR and BRAF inhibition (Cetuximab and Encorafenib), although resistance remains a clinical challenge. This study addresses the unmet need for disseminating <i>BRAF</i>MT …
-
Predicting Early Discontinuation of Adjuvant Chemotherapy and its Impact on Survival among Individuals with Stage III Colon Cancer
… 0.52-0.68) but not among among those prescribed FOLFOX or CAPOX (HR: 0.80; 95% CI: 0.58-1.09). In a target trial analysis of 485 colon cancer patients, both the overall and subgroup-specific hazard ratios were consistent with those from a randomized trial. Conclusions: Results from this …
-
Avaliação da resposta a longo prazo de células de carcinoma colorretal à 5-fluoruracila e oxaliplatina mimetizando o perfil de tratamento clínico
… que o regime quimioterápico mais utilizado é o FOLFOX (5-fluoruracila + oxaliplatina + leucovorina). Apesar do amplo uso, o mecanismo de ação deste protocolo, especialmente considerando o período entre ciclos de tratamento, bem como os mecanismos envolvidos na frequente resistência de células de …
-
Πληθυσμιακή φαρμακοκινητική μοντελοποίηση της μπεβασιζουμάμπης σε ασθενείς με μεταστατικό καρκίνο του παχέος εντέρου
… drug in combination with chemotherapy (FOLFIRI, FOLFOX or CAPIRI). For this reason, the concentrations of total bevacizumab and free VEGF165 were first determined in different cycles of treatment and then, a pharmacokinetic model for bevacizumab binding to VEGF165 was developed by using nonlinear …
-
Proteomics uncover EPHA2 in cetuximab resistant colorectal cancer cell lines as a potential novel therapeutic target
… are typically treated with double chemotherapy (FOLFOX or FOLFIRI) combined with the anti-EGFR targeted monoclonal antibodies cetuximab (CET) or panitumumab. Despite the intensive therapy regimens, 5-year survival rates in metastatic disease are as low as 16%, owing to primary treatment …
-
Μελέτη της μοριακής έκφρασης της θυμιδιλικής συνθάσης και θυμιδιλικής φωσφορυλάσης σε ασθενείς με εξαιρέσιμο ορθοκολικό καρκίνο
… (25.5%), 18 (18.4%) patients were treated with FOLFOX and 13 patients (13.3%) received FOLFIRI. One patient was given FOLFOXIRI and another one received capecitabine monotherapy. Archival formalin-fixed, paraffin-embedded tumor specimens were retrieved from 98 patients. Protein expression …
Page 1 of 2